Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Galectin-7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Galectin-7 Recombinant Protein High purity (>95%), Endotoxin Controlled (<1.0 EU/μg). Sequence Verified. HEK293 expressed for native conformation. |
View Galectin-7 Products |
| Gene Delivery | Galectin-7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and functional overexpression assays. |
View Galectin-7 Products |
| Benchmark Ab | Anti-Galectin-7 Recombinant Antibody High-affinity positive control for ELISA, Flow Cytometry, and neutralization assays. |
View Galectin-7 Products |
| Validator | Galectin-7 siRNA Set Target-specific knockdown pool for functional validation and specificity controls. |
View Galectin-7 Products |
| Related Target A | Galectin-3 Key homologous lectin. Essential for off-target counter-screening and selectivity profiling. |
View Galectin-3 Products |
| Related Target B | Galectin-1 Synergistic immune-checkpoint lectin in the tumor microenvironment; target for dual-action therapeutic screening. |
View Galectin-1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-Target Cross-Reactivity | High-purity homologous panels (Galectin-1, Galectin-3) strictly verified by SDS-PAGE and Mass Spectrometry. |
| Dimeric Conformation Preservation | HEK293 expression system ensures native folding and homodimeric presentation of Galectin-7. |
| Lack of Benchmarking Controls | Sequence-verified clinical benchmark antibodies available as reference standards. |
| Assay Artifacts & False Positives | Sequence-verified siRNA sets included to confirm knockdown specificity in phenotypic assays. |
Live Galectin-7/LGALS7B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Galectin-7 (LGALS7/LGALS7B) is emerging as a compelling frontier in oncology and dermatology. Historically recognized for its role in stratified squamous epithelium, preclinical studies have highlighted Galectin-7 as a major promoter of immunosuppression, metastasis, and chemoresistance in aggressive solid tumors, such as breast, ovarian, and oral squamous cell carcinomas. Conversely, its pro-apoptotic role in specific tissue contexts demands highly precise targeting strategies.
The race for Galectin-7 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum carbohydrate mimetics to highly selective monoclonal antibodies (mAbs) and small-molecule inhibitors targeting the carbohydrate-recognition domain (CRD). As first-generation therapies reach the clinic, the next wave of R&D is targeting synergistic combinations with established immune checkpoint inhibitors (such as anti-PD-1/PD-L1) and the development of bispecific agents to overcome the immunosuppressive tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Biotech Innovators, Academic Medical Centers | Triple-Negative Breast Cancer (TNBC), Epithelial Ovarian Cancer | Epitope mapping & neutralization assays (Need high-purity, native homodimeric Galectin-7 antigen) |
| Small Molecule Inhibitors | Pharmaceutical Research Institutes | Squamous Cell Carcinomas, Psoriasis | Carbohydrate-Recognition Domain (CRD) competitive binding assays (Need structurally validated recombinant proteins) |
| Combination Therapies | Oncology-focused Biopharma | Refractory Solid Tumors | In vitro immune cell co-culture assays (Need endotoxin-controlled proteins and validated knockdown siRNA) |